Miragen Preps for Series B, Expects First IND in 2011
July 15, 2010
Miragen Preps for Series B, Expects First IND in 2011
The expected size of the round is not being disclosed. The financing will be "just enough to support a couple programs moving forward and the continued operations of the company," Miragen President and CEO Bill Marshall said.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Miragen Closes $20M Series B Financing
April 26, 2012 / Gene Silencing News - Miragen, University of Colorado Collaborate on microRNA Research
October 28, 2010 / Gene Silencing News - Santaris, Miragen Form miRNA Drug Alliance
June 24, 2010 / Gene Silencing News - Miragen Licenses miR-145 IP from University of Glasgow
March 7, 2013 / Gene Silencing News - Santaris, Miragen Expand microRNA Partnership to Include Additional Targets
January 10, 2013 / Gene Silencing News